Core Insights - Amphastar Pharmaceuticals reported revenue of $174.41 million for the quarter ended June 2025, a decrease of 4.4% year-over-year, with EPS at $0.85 compared to $0.94 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $169.84 million, resulting in a surprise of +2.69%, while the EPS surprised by +19.72% against the consensus estimate of $0.71 [1] Revenue Breakdown - Primatene MIST generated net revenues of $22.88 million, slightly below the average estimate of $25.95 million, reflecting a year-over-year change of +0.1% [4] - Glucagon reported net revenues of $20.6 million, significantly lower than the average estimate of $28.32 million, marking a year-over-year decline of -24.7% [4] - Lidocaine achieved net revenues of $15 million, surpassing the average estimate of $13.14 million, with a year-over-year increase of +17.2% [4] - Epinephrine's net revenues were $16.18 million, falling short of the average estimate of $17.77 million, indicating a year-over-year decrease of -42.1% [4] Stock Performance - Amphastar's shares have returned -7.2% over the past month, contrasting with the Zacks S&P 500 composite's +1.2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]

Core Insights - Amphastar Pharmaceuticals reported revenue of $170.53 million for the quarter ended March 2025, reflecting a year-over-year decline of 0.8% [1] - The earnings per share (EPS) for the same period was $0.74, down from $1.04 a year ago, with a surprise of +12.12% compared to the consensus estimate of $0.66 [1] - The reported revenue was a surprise of -0.69% against the Zacks Consensus Estimate of $171.71 million [1] Revenue Breakdown - Primatene MIST generated net revenues of $29.05 million, exceeding the average estimate of $27.64 million, representing a year-over-year increase of +20.2% [4] - Glucagon reported net revenues of $20.84 million, slightly above the estimated $20.24 million, but showed a year-over-year decline of -27% [4] - Lidocaine achieved net revenues of $13.64 million, surpassing the average estimate of $13.15 million, with a year-over-year increase of +6.8% [4] - Epinephrine's net revenues were $18.59 million, above the estimated $18.21 million, but reflected a significant year-over-year decline of -28.8% [4] Stock Performance - Amphastar's shares returned +0.5% over the past month, while the Zacks S&P 500 composite increased by +10.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]